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 Abstract 
 
Introduction. To study the effect of rosuvastatin on endothelial and macrovascular function, 
cardiovascular risk factors and the complement pathway in patients with systemic sclerosis 
(SSc). 
Methods. Altogether 28 patients with SSc underwent laboratory and complex vascular 
assessments before and after 6 months of 20mg rosuvastatin treatment. Flow-mediated 
dilation (FMD) of the brachial artery, as well as carotid artery intima-media thickness 
(ccIMT), carotid-femoral and aorto-femoral pulse wave-velocity (PWV) were analyzed by 
ECG-synchronized ultrasound. Ankle-brachial index (ABI) was determined by Doppler, 
forearm skin microcirculation was assessed by Laser Doppler perfusion monitoring. 
Results. Brachial artery FMD  significantly improved upon rosuvastatin therapy (2.2±3.3% 
before vs. 5.7±3.9% after treatment, p=0.0002). With regards to patient subsets, FMD 
significantly improved in the 21 lcSSc patients (from 2.1% to 5.6%; p=0.001). In the 7 dcSSc 
patients, we observed a tendency of improvement in FMD (from 3% to 6%; p=0.25). Changes 
in PWV, ccIMT and ABI were not significant. Mean triglyceride (1.7±0.97 vs. 1.3±0.46 
mmol/l, p=0.0004), total cholesterol (5.3±1.6 mmol/l vs. 4.2±1.3 mmol/l, p=0.0003), LDL-C 
(3.0±1.3 vs. 2.2±1.0 mmol/l, p=0.005) and CRP levels (5.1±5.2 vs. 3.4±2.7, p=0.01) levels 
significantly decreased after rosuvastatin treatment. Mean C3, C4 and IC levels also 
decreased significantly as compared to pretreatment values. 
Conclusions. Six-month rosuvastatin therapy improves endothelial function and lowers CRP, 
C3, C4 and IC levels indicating possible favourable effects of this statin on the cardiovascular 
and immune system in SSc.  
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Introduction 
 
Systemic sclerosis (SSc) is a systemic autoimmune disease of uncertain etiology 
characterized by progressive fibrosis of the skin, the small blood vessels and various internal 
organs. Population-based and other cohort studies have emphasized that survival is decreased 
in patients with SSc [1-3]. Several reports including our previous studies, have found 
macrovascular abnormalities in SSc patients. These include endothelial dysfunction indicated 
by abnormally low flow-mediated dilation (FMD) of the brachial artery [4, 5], increased 
carotid intima-media thickness (IMT) and increased arterial stiffness [6-8]. Statins may 
improve endothelial dysfunction, arterial stiffness and reduce levels of inflammatory markers 
in various conditions including chronic kidney disease, rheumatoid arthritis and dyslipidemia. 
In SSc, the vascular effects of atorvastatin, simvastatin and pravastatin have been investigated 
so far [9]. Atorvastatin exerted beneficial effects on microvascular function, digital ulcers, 
soluble markers of endothelial function, as well as FMD [10, 11]. Simvastatin and pravastatin 
reduced the production of soluble endothelial activation markers [12, 13].  
It is not fully clear which of the multiple mechanisms of statins may be involved in 
SSc-related vascular changes. Although a pronounced reduction of LDL-cholesterol is present 
in patients undergoing statin therapy, additional mechanisms have been suggested to  improve 
endothelium-dependent vasodilation  in case of HMG-coA reductase inhibitor therapy. A key 
point is promoting activity of the endothelial NO synthase. This can either be caused by a 
weakened interaction between the endothelial NO synthase (eNOS) and caveolin-1, or the 
association of e-NOS and hsp90, as well as by an upregulation of eNOS mRNA by inhibition 
of the Rho kinase pathway or a reduction in ICAM-1 and P-selectin levels, which also result 
in increased endothelial NO production [14]. 
In this study, we wished to determine the effects of rosuvastatin, a potent reducer of 
total (TC) and LDL cholesterol (LDL-C) [15, 16], on serum inflammatory markers and 
complement levels, on endothelial and macrovascular function, as well as on arterial stiffness 
in patients with SSc. In addition, we determined the possible effects of rosuvastatin on 
microvascular function, by assessing cutaneous blood flow. The primary endpoint of the study 
was rosuvastatin effects ont he vasculature (FMD, ccIMT, PWV, ABI), while the secondary 
outcome included laboratory marker changes (lipids, CRP, immune complexes and 
complement). The assessment of acute phase reactants and complement has been included in 
scleroderma activity index [17]. 
 
Materials and methods 
 
Patients 
 
SSc patients undergoing follow-ups at our institution were randomly screened for 
inclusion and exclusion criteria described below. Altogether 28 patients including 25 females 
and 3 males were eligible for the study. The diagnosis was established according to the 1980 
ACR criteria for SSc [18]. The mean age of patients was 60.4 ± 11.0 years (range: 34-83 
years), the mean disease duration was 13.6 ± 7.7 years (range 2-30 years). Among these 
patients, 21 (75%) had the limited (lcSSc) and 7 (25%) had the diffuse cutaneous form of SSc 
(dcSSc). Clinical manifestations of SSc included Raynaud’s phenomenon (96%), distal skin 
manifestations including sclerosis and ulcers (68%), proximal skin involvement (25%), 
cardiac manifestations including conduction defects, atrial fibrillation, arrhythmias (25%), 
gastrointestinal manifestations, such as esophageal dysmotility, gastroesophageal reflux 
(54%), renal involvement (4%) and sicca syndrome (10%). Altogether 6 patients (22%) had 
an overlap syndrome with another autoimmune disease: two patients had poly-
dermatomyositis, one had systemic lupus erythematosus and 3 had rheumatoid arthritis in 
addition to SSc. The patients’ medications are listed in Table 1. All recruited patients were 
non-smokers and their mean body mass index (BMI) was 23.1 ± 4.1 kg/m2. 
Patients were included in the study if lcSSc or dcSSc was present, and the patients 
exhibited microvascular symptoms including new digital ulcers, active Raynaud’s symptoms 
despite ongoing therapy. Patients had not been on any lipid lowering drug therapy for the past 
6 months prior to this study. 
Exclusion criteria included hyperglycemia, acute systemic infection, uncontrolled 
hypertension, carotid sinus hyperesthesia, permanent atrial fibrillation, an ejection fraction 
(EF) less than 50% as determined by echocardiography, severe pulmonary arterial 
hypertension (PAH), active ulcers at any of the measurement sites or lack of patients’ 
informed consent. 
Approximately 60 patients were screened for the study. Thus, 28 patients meeting the 
inclusion criteria were included. Any patients meeting any exclusion criteria, those on 
vasoactive drugs, such as prostanoids or patients undergoing frequent treatment modifications 
were excluded.   
Written informed consent was obtained from all subjects. The study was performed 
according to the Declaration of Helsinki under the auspices of the University of Debrecen 
Research Ethics Committee and the ETT-TUKEB central Ethics Committee (No. 14804-
1/2011-1018EKU)..   
   
Study protocol 
 
Both laboratory analyses and the clinical examinations described below were 
performed on two occasions, directly before and after the rosuvastatin treatment period. Each 
patient recieved 20 mg rosuvastatin daily for 6 months. All patients tolerated the drugs well 
and all of them could complete the study. On the day of vascular assessments, blood samples 
were drawn between 7 and 8 a.m. after an 8-hour fasting period. Samples were stored at room 
temperature and analyses were performed within 2 hours. Von Willebrand factor antigen 
(vWF) samples were stored on ice until analysis. Before vascular assessments, the use of 
vasoactive and antioxidant drugs, as well as alcohol or caffeine consumption were suspended 
for 24 hours. Examinations were performed under standardized conditions after a 10-minute 
resting period in a recumbent position. Vascular assessments were carried out in a quiet, 
darkened study room with a temperature of 22±1 oC according to the recommendations of 
Laurent et al [19]. All assessments were performed by a single observer (O.T.) 
 
Vascular assessments 
 
Brachial artery FMD assessment was performed by the same skilled operator 
according to the methodology described by Corretti et al [20] under standardized conditions 
[21] using a 10 MHz linear array transducer of a HP Sonos 5500 (Hewlett Packard) 
ultrasound equipment.  Briefly, longitudinal section of the brachial artery of supine patients 4-
7 cms proximal from the antecubital fossa was obtained at end-diastole (upon R wave of 
ECG) and the arterial diameter (BADbasal), namely the distance between the proximal and 
distal media-adventitia borders, was measured. Results of five repeated measurements were 
averaged. After 4.5 minutes of distal (forearm) blood pressure cuff occlusion with 50 Hgmm 
suprasystolic pressure, reactive hyperaemia-induced maximal diameters (BADmax) were 
measured within 3 minutes after release. Images were digitized for further documentation. 
FMD was calculated as [(BADmax-BAD basal)/BADbasal] x 100 and expressed in % compared to 
the basal diameter. The intraobserver variability of FMD was excellent: the calculated 
coefficient of variation (CV) and intraclass correlation coefficient (ICC) were 5% and 0.935, 
respectively, indicating very good reproducibility. 
 Aorto-femoral pulse wave velocity (c-fPWV) was measured as previously described 
elsewhere [22] on a HP Sonos 5500 ultrasound equipment with simoultaneous ECG 
recording. Carotid-femoral pulse wave velocity (c-fPWV) was measured during the same 
examination with minor changes compared to the a-f PWV assessment. C-f PWV was 
determined between the left common carotid artery, 1 cm proximal to the bifurcation and the 
right common femoral artery at the level of the inguinal ligament using the linear array 
transducer. The distance between the two sites was defined as the difference between the 
sternal jugulum - carotid measurement point distance and the sternal jugulum-femoral 
measurement point distance. C-f PWV was again the quotient of the distance and the transit 
time, the time difference between the foot-to-foot intervals gained at the two measurement 
sites [23-25]. 
 Common carotid artery intima-media thickness (ccIMT) was measured according to 
current guidelines [26] by the same examiner with the HP Sonos 5500 ultrasound equipment 
described above. Briefly, longitudinal B-mode views of the common carotid arteries were 
taken by medio-lateral probe position, then high magnification images were frozen at end-
diastole. ccIMT, defined as the distance between the first and second echogenic lines 
corresponding the intima-lumen and media-adventitia interfaces, respectively, was measured 
offline 1 cm from the carotid bulb or the nearest plaque-free segment on the far wall 
according to the leading edge principle. Ten measurements were performed and averaged on 
either side and the value of ccIMT was expressed in millimeters. The intraobserver variability 
of ccIMT was excellent: the calculated CV and ICC were 4.2% and 0.98, respectively,  
indicating very good reproducibility. 
Assessment of ankle-brachial index (ABI) was carried out according to TASC II. 
guidelines [27]. A 10-12 cm sphygmomanometer cuff was placed just above the ankle and a 
handheld CW Doppler instrument (Vasodop 8 MHz, MediCAD Ltd, Miskolc, Hungary) was 
used to measure the systolic pressure of the posterior tibial and dorsal pedal artery of each leg. 
The higher of these pressures was divided by the higher brachial systolic blood pressure value 
to form the ABI. 
Microvascular skin perfusion was assessed by Laser Doppler (LD) perfusion 
monitoring [28]. During this examination, a 780 nm wavelength laser beam penetrates the 
skin to a depth of 1-1.5 mm and a fraction of the light is scattered back by moving blood cells 
resulting in a frequency shift according to the Doppler principle. Therefore a signal 
proportional to tissue perfusion is generated. Provocation tests such as heat, postocclusive 
reactive hyperemia (PORH) or biochemical agents applied by iontophoresis allow for testing 
skin  reactivity. We applied a standard laser probe (PF 408) fixed in a straight probe holder 
(PH 08) of a Periflux PF 4001 LD flowmeter (Perimed AB, Järfällä, Sweden). The LD 
apparatus was connected to a laptop, which displayed recordings and saved the information 
for further offline analysis by the Perisoft for Windows (Ver. 2.5.5) software (Perimed AB). 
Measurements were carried out with the patients in a supine position. The probes were placed 
on the volar side of mid-forearm skin, avoiding superficial subcutaneus blood vessels and 
basal blood flow was recorded for 8 minutes. Afterwards, during continuous recording of skin 
blood flow, upper arm was obstructed for a three minute period by a 10-12 cm 
sphygmomanometer cuff inflated to 50 Hgmm suprasystolic pressure, then cuffs were 
suddenly deflated and forearm skin blood flow was further recorded for 5 minutes. During 
this period, blood flow returned to baseline. Blood flow (basal, peak, biological zero) was 
expressed in arbitrary perfusion units (PU) and relative changes compared to basal values 
were assessed, time to half before hyperaemia (TH1, sec), time to maximum flow (TM, sec) 
and time to half recovery (TH2, sec) were analysed, and the occlusion areas (AO), 
hyperaemic areas under curve (AH, PU*sec), as well as hyperemia repayment (AH/AO) were 
determined. In addition, we assessed the slope of the curve as it reached maximum perfusion 
after cuff release (acceleration slope) and upon return to basal skin flow (deceleration slope). 
 
Laboratory analyses 
 
Serum biochemical markers and high sensitivity CRP (hsCRP) were analysed on a 
Modular P-800 analyser (Roche Ltd, Mannheim, Germany). Serum total cholesterol, 
triglyceride and uric acid levels were determined by enzymatic colorimetric assay, HDL and 
LDL- cholesterol were analysed by homogenous enzymatic assay. Serum glucose and urea 
levels were measured using enzyme kinetic UV assay, serum creatinine was determined by 
the compensated Jaffe kinetic method. Estimated GFR was calculated from the serum 
creatinine by the MDRD 175 (Modification of Diet in Renal Disease study group) formula. 
HsCRP was assessed by wide range immunoturbidimetric assay, hsCRP levels >5 mg/l were 
considered elevated. 
Plasma levels of circulating vWF, a marker of endothelial cell activation was 
determined by STA Liatest vWF immunoturbidimetric assay using microlatex particles coated 
with polyclonal rabbit anti-human vWF antibodies (Diagnostica Stago, Asnieres, France). 
After mixing the reagent with plasma, the degree of agglutination was proportional to the 
amount of vWF present in the plasma sample. The reference range for the test is 50-160%.  
Hematological parameters including hemoglobin (Hgb), white blood cell and platelet 
counts were determined using a Sysmex XE-2100D automated haematology analyzer 
(Sysmex Corp., Kobe, Japan). Erythrocyte sedimentation rate (ESR) was determined by the 
Westergren method.  
Circulating immune complexes (IC) were detected by polyethylene glycol 
precipitation method. Serum complement C3 and C4 levels were measured by nephelometry 
on a Siemens-Dade-Behring BN-II nephelometer. Laboratory reference ranges were 0.9-1.8 
g/l for C3, 0,1-0.4 g/l for C4 and an extinction of 0-170 for IC. 
 
Statistical analysis 
 
Due to the nature of the study (before/after comparison), paired one-tailed/two-tailed t-
tests were used for statistical evaluation. P values < 0.05 were considered significant. Data 
represent a normal distribution, as shown by the Kolmogorov-Smirnov test. Correlations were 
assessed using SPSS software version 11.0. The Pearson correlation coefficients were 
determined and r values at the p<0.05 level were considered significant. 
 
 
Results 
 
Effects of rosuvastatin on micro-and macrovascular function 
 
FMD significantly improved after 6 months of rosuvastatin therapy (2.3±3.3% before 
vs 5.7±3.9% after treatment, p=0.0002) (Table 2). Altogether 23 patients responded with an 
increase in occlusion-provoked vasodilation of the brachial artery following rosuvastatin 
treatm FMD and serum cholesterol, LDL or HDL level changes. 
With regards to patient subsets, FMD significantly improved in the 21 lcSSc patients, 
from 2.1% to 5.6% (p=0.001). In the 7 dcSSc patients, we observed a tendency of 
improvement in FMD, from 3% to 6% (p=0.25). The non-significant change in dcSSc may be 
the result of low patient number (data not shown). 
In 11 of the 28 patients (39.3%), baseline carotid-femoral PWV (c-fPWV) values were 
above the average reference values of age-, lipid- and blood-pressure-status-matched 
European patients [29] (Table 2). Neither aorto-femoral, nor carotid-femoral PWV showed 
significant improvement upon rosuvastatin treatment (a-f PWV: 8.8±2.2 m/s before, vs. 
8.3±2.1 m/s after therapy, p=0.15; c-f PWV: 8.7±2.6 m/s before vs. 8.1±1.9 m/s after 
treatment, p=0.1) (Table 2). However, by the end of rosuvastatin treatment, only 5/28 patients 
(17.9%) had c-fPWV above the mentioned reference values.  
The mean ABI, indicator of peripheral arterial disease, was 1.1±0.2 on both sides and 
remained unchanged after rosuvastatin therapy (Table 2).  
Ultrasound analysis of the common carotid arteries revealed a mean ccIMT of 
0.68±0.14 mm on the right and 0.72±0.17 mm on the left side at baseline. After rosuvastatin 
therapy, these values were 0.68±0.14 mm (p=0.38) and 0.70±0.17 mm (p=0.3), respectively 
(Table 2). Thus, statin treatment did not result in any improvement in carotid atherosclerosis.  
Laser Doppler analysis of the forearm skin flow during PORH testing revealed 
decreases in the acceleration and deceleration slope of the curves following rosuvastatin 
therapy compared to pretreatment values (acceleration slope: 14.6±14.8 vs. 10.0±10.3 U/sec; 
p=0.081; deceleration slope: -1.13±0.92 U/s vs -0.64±1.09 U/s; p=0.021) (Table 2). Neither 
basal, peak or biological zero skin perfusion, nor AH or any of the time characteristics (TM, 
TH1, TH2) showed significant changes compared to pretreatment values (data not shown).  
 
Laboratory parameters 
 
The presence of antinuclear autoantibodies (ANA) among patients was the following: 
26/28 patients (93%) were ANA positive, 12/28 patients (43%) had antibodies against 
extractable nuclear antigen (ENA), 1/28 (4%) against nuclear ribonucleoproteins (RNP), none 
against Smith antigen (Sm), 3/28 patients (11%) against SS-A (Ro) antigen, none against SS-
B (La), 12/28 patients (43%) tested positive for antibodies against topoisomerase I (Scl-70), 
and 2/28 (7%) were positive for antibodies against histidyl-tRNA synthetase (Jo-1). 
Baseline serum lipid levels indicated that 10% of patients had hypertriglyceridaemia 
(TG >2.3 mmol/l), 50% had hypercholesterolemia (total cholesterol>5.2 mmol/l) and 32 % 
had elevated LDL-C levels (>3.4 mmol/l). At baseline, 11 out of 28 patients (39%) had low 
HDL-C levels (<1.2/<1.0 mmol/l for females/males, respectively). Reference values were 
determined as recommended for the medium cardiovascular risk group based on the European 
SCORE chart [30].  
Among blood chemistry values, lipid parameters showed significant improvement after 6 
months of rosuvastatin therapy. Mean TG levels decreased from 1.70± 0.97 mmol/l to 
1.30±0.46 mmol/l following therapy (p=0.0004). Total cholesterol decreased from 5.3±1.6 
mmol/l to 4.2±1.3 mmol/l (P=0.0003),  LDL-C levels decreased from 3.0±1.3 mmol/l to  
2.2±1.0 mmol/ (P=0.0046), while mean HDL-C levels remained unchanged (1.5±0.8 mmol/l 
before vs. 1.5±0.6 mmol/l after therapy, p=0.33) (Table 3). Non-HDL cholesterol levels also 
displayed a significant decrease after statin therapy (3.8±1.5 vs. 2.5±1.3 mmol/l, p=0.0003.) 
Among acute phase reactants, hsCRP levels showed a significant decrease, from 
5.1±5.2 mg/l to 3.4±2.7 mg/l (p=0.01). Erythrocyte sedimentation rate (ESR), renal function 
tests and full blood counts exerted no biologically relevant changes upon statin therapy as 
compared to baseline values (Table 3). 
Baseline circulating vWF antigen levels were abnormally high in 63% of patients and 
although mean vWF antigen levels showed a slight decrease after rosuvastatin treatment 
(209±90% vs. 193±76%), this change remained statistically insignificant (p=0.09) (Table 3). 
Serum immune complex levels (IC) were initially elevated and levels returned to 
normal after rosuvastatin therapy (extinction: 183.6 vs. 135.5, respectively, p=0.007), while 
C3 (1.81 vs. 1.62 g/l) and C4 levels (0.33 vs. 0.27 g/l) displayed a significant decrease after 
rosuvastatin treatment (p=0.001) within the reference range. 
There were no significant differences in any laboratory parameters with regards to 
rosuvastatin treatment in lcSSc vs dcSSc (data not shown). 
 
 
Discussions 
 
We have previously described impaired FMD in SSc patients compared to age- and 
sex-matched controls [5]. Our current pretreatment FMD results in scleroderma patients are in 
concordance with our previous measurements. The detected significant improvement in 
endothelial function following 6 months of rosuvastatin treatment, however, is a novel finding 
which had not been demonstrated in SSc patients before. Comparing this effect of 
rosuvastatin to vascular effects of atorvastatin treatment reported by other investigators [31-
34], it is likely that the two statins are similar with respect to their effect on endothelial 
function (FMD). Whether favourable effects of rosuvastatin on endothelial function is also 
accompanied by improvement in clinical vascular symptoms such as Raynaud’s phenomenon, 
digital ulceration or Rodnan skin score in SSc has yet to be investigated.   
The duration of therapy is a decisive feature of successive statin treatment in SSc. 
While in one study [33] an 8-week atorvastatin (20 mg) treatment in SSc exhibited no effect 
on endothelial function as assessed by Laser Doppler imaging, another [34] described 
beneficial effects of 24 month atorvastatin (10 mg) therapy on Raynaud’s phenomenon of SSc 
patients. Thus, the beneficial effects of statins on the vasculature, as well as on the underlying 
inflammatory disease may be expected only after 6 months or more.  
As recently reviewed [35], there is an ongoing debate about the extent and presence of 
atherosclerosis in patients with SSc. By assessing ccIMT, PWV, FMD and ABI we wished to 
confer further data to this debate.  
In our present study, the mean pretreatment values of right and left ccIMT were within 
the 25th and 75th percentile range of the given age group as described in large-scale European 
cohort studies [36, 37]. Our current findings support the results of studies reporting normal 
ccIMT in scleroderma patients and it seems these studies outnumber those detecting 
abnormally high ccIMT values [35]. Baseline ABI values were also normal in this study, in 
corcordance with other studies describing either normal or mildly reduced ABI in SSc patients 
[35]. Regarding changes after 6 months of rosuvastatin therapy, our assumptions of 
favourable outcome were based on the results of previously conducted clinical trials with 
rosuvastatin on nonrheumatic patients and on a few pilot studies with rosuvastatin in patients 
with RA or hyperlipidaemia. Two-year treatment with high-dose rosuvastatin has been shown 
to result in regression of coronary atherosclerosis, as documented by intravascular ultrasound 
and quantitative coronary angiography [38, 39]. In the METEOR study, 40 mg rosuvastatin 
resulted in significant reduction in the rate progression of maximum ccIMT values over 2 
years in middle-aged patients with subclinical atherosclerosis [40]. Yet, our present findings 
suggest that 6 months of rosuvastatin (20 mg) therapy yields no change in mean ccIMT in 
scleroderma patients. The reasons why we could not detect similar changes as the 
investigators in the METEOR study could be the lower dose and shorter duration of 
rosuvastatin therapy.  
The frequency of PWV values above mean European reference values [29] decreased 
from 11/28 to 5/28 following rosuvastatin therapy. Somewhat suprisingly, a-f and c-fPWV 
were elevated only in 39% of patients in this study and mean values exhibited no statistically 
significant changes following rosuvastatin therapy. Multiple explanations including 
concomittant use of calcium channel blockers and/or ACE-inhibitors (Table 1), the duration 
of statin therapy may arise. In order to interpret our results appropriately, repetition of these 
examinations with longer treatment periods and comparison with PWV progression of 
nontreated patients will be required. 
  Adding Laser Doppler measurements to our study protocol was decided as some 
studies had previously indicated impaired cutaneous vasodilatory response to ischemia in SSc 
patients [41]. Our Laser Doppler flowmetry measurements revealed significantly slower 
deceleration slope during PORH testing after rosuvastatin of the forearm skin compared to 
pretreatment values. Yet, the relevance of these slopes in determining microcirculation has 
not yet been fully determined. 
 Among laboratory parameters, in our current study marked reductions in total TG, 
total and non-HDL cholesterol as well as LDL-C cholesterol were observed after 6 months of 
rosuvastatin treatment. HDL-C levels remained unchanged after therapy, however, the 
frequency of HDL-C levels below normal decreased. The changes in total cholesterol and 
LDL-levels correspond to the expectations based on results of clinical trials conducted 
previously to assess efficacy of rosuvastatin in comparison with other statins [15, 16, 42]. A 
possible explanation for not observing significant changes in HDL-C levels may be the fact 
that the majority of SSc patients exerted HDL-C levels within normal range at baseline. 
Among inflammatory markers, hsCRP levels significantly decreased following 
rosuvastatin treatment. Rosuvastatin reduces CRP levels in low cardiovascular risk 
individuals in the general population [43]. There is substantial evidence that hsCRP is an 
independent cardiovascular risk factor in the general population, but its predictive value in 
early stages of atherosclerosis is doubtful [44, 45]. To our best knowledge, this is the first 
study to show that CRP levels improve after 6 months of 20 mg rosuvastatin therapy in 
patients with SSc.  
Levels of circulating vWF antigen have been found elevated in patients with 
Raynaud’s phenomenon and SSc [46] as a sign of endothelial injury. In our patient cohort, 
rosuvastatin treatment resulted in slight, non-significant decrease in elevated circulating vWF 
levels.   
Although the exact pathomechanism of SSc is yet unknown, lately, activation of the 
complement system has been suggested and immune complex deposition, particularly in the 
perivascular and subendothelial region has been described [47]. In our current study we 
observed elevated serum immune complex levels returning to normal following rosuvastatin 
treatment. In addition, C3 and C4 levels showed a significant decrease after rosuvastatin 
treatment.  
  
Conclusions 
 
In conclusion, rosuvastatin improves brachial artery FMD, corrects dyslipidemia and 
decreases CRP, complement 3 and 4 and immune complex levels, while it may not reduce 
arterial stiffness or carotid atherosclerosis following a 6-month treatment period in SSc 
patients with intermediate cardiovascular risk. More long-term studies carried out in larger 
patient cohorts are needed to determine the place of rosuvastatin and other statins in the 
therapy of SSc and to find the right agent capable of improving cardiovascular outcome in 
these patients. 
 
Key messages 
 
- Accelerated atherosclerosis and vasculopathy have been associated with systemic 
sclerosis 
- Statins may have beneficial effects on vascular function in SSc 
- In our study, rosuvastatin improved endothelial function (FMD) and decreased CRP 
levels suggesting a possible link between inflammation and vasculopathy in SSc 
- complement 3, 4 and immune complex levels also decreased upon rosuvastatin 
treatment  
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 Table 1. Pharmacological therapy of  SSc patients at inclusion 
 
 
Medication Number of patients % 
ARB/ACE inhibitors 21 75 
Calcium channel blockers 16 57 
Beta blockers 8 29 
Corticosteroids 9 32 
Pentoxifylline 23 82 
Nitroglycerine 4 14 
Vitamin E 8 29 
Platelet Aggregation Inhibitors 16 57 
H2-receptor blockers or proton-pump inhibitors  14 50 
Immunosuppressive agents 3 11 
NSAIDs 5 18 
Bisphosphonates 3 11 
Others (diuretics, tramadol, benzodiazepines, 
bronchodilators) 
14 50 
Table 2. Vascular assessments before and after rosuvastatin treatment in SSc patients 
 
Parameter Pre-treatment mean 
(S.D.) 
Post-treatment mean 
(S.D.) 
P value* 
FMD  (%) 2.3 (3.3) 5.7 (3.9) 0.0002 
Right ccIMT (mm) 0.675 (0.144) 0.681 (0.142) ns (0.38) 
Left ccIMT (mm) 0.717 (0.172) 0.701 (0.165) ns (0.3) 
Carotid-femoral PWV (m/s) 8.7 (2.6) 8.1 (1.9) ns (0.1) 
Aorto-femoral PWV (m/s) 8.8 (2.2) 8.3 (2.1) ns (0.15) 
Right Ankle-Brachial Index  1.1 (0.16) 1.1 (0.27) ns (0.4) 
Left Ankle-Brachial Index  1.1 (0.14) 1.1 (0.19) ns (0.4) 
Laser Doppler acceleration slope (U/s) 14.6 (14.8) 10.0 (10.3) ns (0.08) 
Laser Doppler deceleration slope (U/s) -1.13 (0.92) -0.64 (1.09) 0.021 
 
*Significant differences are indicated in bold. ns: non significant 
Table 3. Laboratory parameters before and after rosuvastatin treatment in SSc patients 
 
Parameter Pre-treatment mean (S.D.) Post-treatment mean (S.D.) P value* 
Erythrocyte sedimentation rate (mm/h) 21 (15.6) 24.7 (19) ns (0.15)  
CRP (mg/l) 5.1 (5.2) 3.4 (2.7) 0.01 
Glucose (mmol/l) 5.3 (1.0) 5.5 (1.3) ns (0.24) 
Urea (mmol/l) 6.0 (2.4) 5.9 (2.5) ns (0.5) 
Creatinine (µmol/l) 67.5 (19.7) 63 (16.9) ns (0.062) 
GFR (ml/min)  82.1 (14.0) 84.8 (10.8) ns (0.078) 
Triglyceride (mmol/l) 1.7 (0.97) 1.3 (0.46) 0.0004 
Total cholesterol (mmol/l) 5.3 (1.57) 4.2 (1.28) 0.0003 
LDL (mmol/l) 3.0 (1.3) 2.2 (1.0) 0.005 
Non-HDL (mmol/l) 3.8 (1.5) 2.5 (1.3) 0.0003 
HDL (mmol/l) 1.5 (0.84) 1.5 (0.6) ns (0.33) 
Uric acid (µmol/l) 263 (56) 273 (77) ns (0.22) 
von Willebrand factor (%) 209 (90) 193 (75.6) ns (0.092) 
Hemoglobin (g/l) 125 (12.7) 126 (12.5) ns (0.242) 
White blood cell count (109/l) 6.7 (2.6) 7.1 (2.7) ns (0.191) 
Platelet count (109/l) 250 (62) 265 (64.5) ns (0.064) 
Complement 3 (g/l) 1.81 (0.4) 1.62 (0.32) 0.001 
Complement 4 (g/l) 0.31 (0.13) 0.27 (0.1) 0.001 
Immune complex (extinction) 183.6 (110) 135.5 (55) 0.005 
*Significant differences are indicated in bold, ns: non-significant. 
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